Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference
CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on...
News
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the...
Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference
Oak Ridge, TN, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement...
Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical...
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
ARLINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research,...
PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference
PRINCETON, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 4
DUBLIN, Ireland, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines...
LifeMD to Report Fourth Quarter 2023 Financial Results on March 11
NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services,...
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
Data expected to be shared during March corporate update With SAD cohorts complete, MAD cohorts to begin dosing in March...
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements
FLORHAM PARK, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage...
Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
A total of 19 patients with serious/life-threatening invasive fungal infections have been enrolled, including aspergillosis, mucormycosis, fusarium, candidiasis, cryptococcosis, and...
Saxony-Anhalt Embraces Change as an Opportunity: Billions Invested in Key Transformation Industries
Companies are currently injecting nearly three billion euros into projects in Saxony-Anhalt, marking a significant commitment to transformative initiatives. When...
MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial
MindBio demonstrates safe, effective take home use of MB22001 in Depressed patients over an 8-week, world first take-home trialRapid, robust,...
Mednition Appoints Deena Brecher as Chief Nursing Officer, Pioneering Commitment to Nurse-First Artificial Intelligence
BURLINGAME, Calif.--(BUSINESS WIRE)--#AI--Mednition, a Silicon Valley leader in clinical artificial intelligence (AI) healthcare solutions, is excited to announce the appointment...
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
- Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose...
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous...
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first...
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first...
Foothold Technology and NY Health Home Coalition Respond to the Impact Budget Cuts Will Have for Vulnerable New Yorkers
NEW YORK--(BUSINESS WIRE)--In response to the recent executive budget decision by Governor Kathy Hochul, which includes a substantial $125 million...
CGFNS International Unveils New Think Tank to Advance Health Workforce Development Scholarship and Solutions Worldwide
PHILADELPHIA, PA / ACCESSWIRE / February 23, 2024 / CGFNS International announced today it has established a Global Health Workforce...